This invention relates to devices intended for removing acute blockages from blood vessels. Acute obstructions may include clot, misplaced devices, migrated devices, large emboli and the like. Thromboembolism occurs when part or all of a thrombus breaks away from the blood vessel wall. This clot (now called an embolus) is then carried in the direction of blood flow. An ischemic stroke may result if the clot lodges in the cerebral vasculature. A pulmonary embolism may result if the clot originates in the venous system or in the right side of the heart and lodges in a pulmonary artery or branch thereof. Clots may also develop and block vessels locally without being released in the form of an embolus—this mechanism is common in the formation of coronary blockages. The invention is particularly suited to removing clot from cerebral arteries in patients suffering acute ischemic stroke (AIS), from coronary native or graft vessels in patients suffering from myocardial infarction (MI), and from pulmonary arteries in patients suffering from pulmonary embolism (PE) and from other peripheral arterial and venous vessels in which clot is causing an occlusion.
According to the invention there is provided a catheter for assisting in the retrieval of a clot from a vessel comprising a distal end and a proximal end, a distal segment and a proximal segment and a lumen extending proximal of the distal end and terminating at a transfer port at the proximal end of the distal segment and a flow restrictor located on the outer surface of the catheter distal of the transfer port.
In one case the catheter is an aspiration catheter for aspirating a clot.
In one embodiment the flow restrictor is actuatable between engaged and disengaged configuration. The catheter may comprise an actuator for selectively engaging and/or disengaging the flow restrictor.
In one case the flow restrictor comprises a framework and a membrane coupled to the framework, the framework being movable by the actuator between an expanded configuration and a retracted configuration.
The aspiration catheter may comprise a proximal flow restrictor proximate the proximal end of the distal segment and a distal flow restrictor spaced distally from the proximal flow restrictor.
In one case the distal end of the catheter comprises a mouth for reception of clot. The mouth may be defined by an expansile tip.
In one embodiment the distal segment includes a hinge adjacent to the distal mouth. The hinge may be defined by a region of the distal segment which is configured to have lateral flexibility.
In one case the mouth has an expanded configuration and a retracted configuration. The catheter may comprise a control member for controlling the movement of the mouth between the expanded and retracted configurations.
In one embodiment the mouth comprises a number of segments and the control member is configured to move at least some of the segments. The control member may comprise a draw string or the like.
In another aspect the invention provides a catheter for aspirating a clot in a vessel comprising a distal end and a proximal end, a distal segment and a proximal segment and a lumen extending proximal of the distal end and terminating at a transfer port at the proximal end of the distal segment wherein the distal end of the catheter comprises a mouth for reception of clot. The mouth may be defined by an expansile tip. In one case the catheter has a flow restrictor located on the outer surface of the catheter distal of the transfer port.
Also provided is a system for treating an occlusion in a vessel the system comprising:—
a first catheter and a second catheter;
the first catheter comprising a proximal end, a distal end and a lumen extending between the proximal end and the distal end, the lumen of the first catheter further comprising a proximal segment and a distal segment;
the second catheter comprising a distal end and a proximal end, a distal segment and a proximal segment, and a lumen, said lumen extending proximal of the distal end and terminating at a transfer port at the proximal end of the distal segment;
the first catheter being configured to facilitate aspiration through the lumen;
the transfer port being configured to transmit aspiration in the proximal lumen of the first catheter into the lumen of the distal segment of the second catheter and the distal end of the second catheter being configured to receive clot into at least a portion of the lumen of the second catheter.
In one embodiment the system further comprises a flow restrictor between the first catheter and the distal segment of the second catheter, distal of the transfer port. The flow restrictor may be located on the inner surface of the first catheter. Alternatively or additionally the flow restrictor is located on the outer surface of the second catheter.
In one embodiment there is a proximal flow restrictor proximate the proximal end of the distal segment of the second catheter and a distal flow restrictor spaced distally from the proximal flow restrictor.
In one case the distal end of the second catheter comprises a mouth for reception of clot. The mouth may be defined by an expansile tip.
In one embodiment the transfer port comprises a rapid exchange port.
In one case the first catheter is a guide catheter. The second catheter may be an intermediate catheter.
The system may also include a microcatheter which is adapted to be advanced through the first catheter and the second catheter. The system may further comprise a clot engaging device for delivery from the microcatheter.
Also provided is a method of removing a clot from a vessel, the method comprising:—
providing a guide catheter and an intermediate catheter, the intermediate catheter having a distal mouth and being configured such that it is advancable within the lumen of the guide catheter;
inserting the guide catheter into a first vessel proximal of an occlusion;
advancing the intermediate catheter through the lumen of the guide catheter until the tip of the intermediate catheter extends distal of the guide catheter into a second vessel adjacent to the occlusion;
applying aspiration to the proximal end of the guide catheter;
the intermediate catheter being configured to direct said aspiration through the distal lumen of the intermediate catheter to aspirate the clot into the mouth of said intermediate catheter.
The aspiration catheter may comprise a distal end, a proximal end, a distal segment, a proximal segment and a lumen extending proximal of the distal end and terminating at a transfer port at the proximal end of the distal segment.
In one embodiment the method comprises restricting flow between the outside surface of the intermediate catheter and the inside surface of the guide catheter.
In one embodiment the method comprises the step, before or after aspiration, of delivering a microcatheter to the occlusion and deploying a clot capture device from the microcatheter. The method may comprise advancing the microcatheter to the clot, deploying a clot capture device from the microcatheter, retracting the microcatheter to a location proximal of a transport port at the proximal end of a distal segment of the aspiration catheter.
In a further aspect the invention provides method of removing an occlusion from a vessel comprising:—
providing a first aspiration catheter and a second aspiration catheter, the second aspiration catheter extending distal of the first aspiration catheter and further comprising a transfer lumen proximal of the distal end of the first aspiration catheter;
inserting the first catheter into a first vessel proximal of the occlusion;
advancing the second catheter through the lumen of the first catheter until the tip of the second catheter extends distal of the first catheter into a second vessel and is substantially opposing the occlusion; and
aspirating through the proximal lumen of the first catheter so as to urge the clot into the distal lumen of the second catheter.
The method may comprise restricting flow between the outside surface of the second catheter and the inside surface of the first catheter.
The method may comprise the step, before or after aspiration, of delivering a microcatheter to the occlusion and deploying a clot capture device from the microcatheter. In one case the method as comprises the step, prior to aspiration, of retracting the microcatheter to a location proximal of the transfer port.
In one embodiment the first aspiration catheter is a guide catheter. In one case the second aspiration catheter is an intermediate catheter.
In one aspect the invention provides a clot receptor device. In one case the device is a catheter which may include rapid exchange features. In one embodiment the device provides a self-expanding aspiration catheter with flow-arrest.
The aspiration assist device has a distal end which expands to seal against the vessel proximal of the clot and provides a large open mouth to receive clot easily without risk of dislodging the clot from the thrombectomy device (if used).
The inner rapid exchange expandable device is delivered through an outer catheter, which may be a conventional intermediate or aspiration catheter or a distal access catheter (DAC). In one case it is a tailored catheter with an extremely trackable distal section for ease of access. This outer catheter trackability is possible because the distal section does not require much axial stiffness, as neither clot not thrombectomy device are retracted directly into it.
The rapid exchange (RX) expanding device may be supplied within the outer catheter (about 15 cm proximal of the distal end) and both are delivered together over a microcatheter (or wire) until the outer catheter tip approaches the clot. The inner RX expanding device is advanced to the distal end of the outer, and the outer is then retracted to deploy the self expanding RX device.
The Rx device seals against the vessel wall and against the inner lumen of the outer catheter to allow highly effective aspiration, and its distal end expands to provide a large opening and reception space to receive the target clot and thrombectomy device (if used).
In another similar embodiment the self expanding aspiration catheter has a full length tubular proximal shaft, rather than a rapid exchange shaft, so that it does not require a proximal seal and aspiration can be applied by applying a vacuum force to its proximal hub.
The invention also provides a rapid exchange aspiration catheter.
The catheter provides a proximal seal against guide catheter inner lumen so that aspiration may be applied through the guide taking advantage of the large proximal lumen.
The catheter having deliverability advantages of minimal frictional engagement with guide or microcatheter proximal of exit port.
Retracting the microcatheter just proximal of exit port (rather than completely removing it) creates a large aspiration advantage.
Also provided is a removable microcatheter hub that enables physician to advance a DAC over the microcatheter after the microcatheter (and thrombectomy device) are already in position (as bail, out for example).
a to 2f illustrate a clot receptor device and system according to the invention;
a to 11d illustrate a rapid exchange aspiration catheter according to the invention;
b illustrate various alternative distal ends and expansile tips of a clot collector device of the invention;
The distal end 8 of the expansile distal section 4 is configured to open to a larger diameter than the proximal end, typically at least 50% larger, and in some embodiments up to 500% larger or more, depending on the relative size of the target blood vessel and the lumen of the catheter 7 through which the device is advanced. The large open mouth of the distal end 8 of the clot receptor 2 provides an easy path for retraction of clot into its interior space, and once within this space the clot can be safely retrieved from the patient. In one embodiment the inner lumen of the clot receptor device 2 has a profiled surface (like a sharkskin, or backward facing teeth) which allows clot to slide easily into the device, but resist the clot from escaping back out of the device.
Many variants of this method are possible.
For example it may be desirable to withdraw the clot 1 and mechanical thrombectomy device 15 through the clot receptor 2, intermediate catheter 7 and guide 11 and out of the patient while leaving the intermediate catheter 7 and clot receptor 2 in place. This allows the physician to retain a protective seal in the vessel to prevent the escape of any clot particles that may be dislodged, and also preserves a means of quick and easy access back to the target site with a microcatheter and thrombectomy device in case additional passes are needed to completely clear the vessel.
Another method variant involves removing the clot receptor device 2 and thrombectomy device 15 together through the intermediate catheter 7, leaving the intermediate catheter 7 in place for easy re-access to the target site.
Yet another method variant involves using the clot receptor device 2 as the primary clot retrieval tool, without the aid of a mechanical thrombectomy device such as a stent-retriever. The clot receptor 2 is configured to expand and seal against the vessel wall adjacent the proximal end of the clot, thus aspirating through the intermediate catheter 7 and clot receptor 2 provides a highly effective suction force to draw the clot into the clot receptor 2. If the clot passes through the clot receptor 2 and into the intermediate catheter 7 it may be aspirated through the intermediate catheter 7 and right out of the patient. If the clot is too large or too firm to pass through the clot receptor 2 then the clot receptor 2 may be withdrawn into the intermediate catheter 7. Because the clot receptor 2 has a smooth and funnel shaped exterior it can be easily retracted into the intermediate catheter 7 even when containing a bulky and/or firm clot.
The distal end 8 of the clot receptor device 2 is intended to open up upon exiting the catheter through which it is delivered to provide a large open mouth approximately equal in size to the inner diameter of the vessel in which it is located and provide a seal against this vessel or significant flow restriction such that when a suction force is applied through the clot receptor 2 this force causes blood and clot distal of the receptor 2 to flow into the receptor 2 rather than blood proximal of the receptor 2. This flow occurs because the pressure inside the clot receptor 2 is lower than that outside (distal and proximal) of the clot receptor 2. If the seal were not present two flow paths into the clot receptor 2 would exist and the less restricted proximal flow path would dominate, reducing the effectiveness of the clot retraction.
In order to adequately seal against the vessel wall the clot receptor 2 should have either a) a high radial force or hoop strength so that the pressure gradient created by the application of suction/aspiration does not collapse the clot receptor or create a flow path past it or b) a seal construction such that the presence of a pressure gradient across the clot receptor 2 serves to tighten the seal rather than reduce it. The geometry and construction of the clot receptor sealing end should be such that it can conform well to the vessel wall, which may be not be effectively circular (such as when close to bifurcations for example, or when inclined at an angle to the vessel wall).
Thus one embodiment of the distal portion of a clot receptor may comprise a self-expanding frame with a relatively non-porous cover, such that the cover prevents any significant passage of blood through the wall of the clot receptor, and the self expanding frame has sufficient radial or hoop strength to resist the pressure gradient created by the application of suction/aspiration. The cover may be a polymeric membrane, or may be a woven or braided or knitted structure. In one embodiment the membrane is a polymer membrane, preferably with a high elastic strain limit and a low modulus to permit its expansion by a low radial force frame structure. A preferred membrane is a polyurethane membrane, which might be extruded or blow moulded or ideally dip coated directly onto the frame. The membrane may be coated with a low friction coating such as a hydrophobic silicone or a hydrophilic material. In one embodiment the membrane is a hydrophilic material itself, comprising a hydrogel with sufficient thickness and modulus to retain its structure under the force of aspiration. Other suitable materials for this cover include PTFE, ETFE and PFA. Materials such as PET, UHMWPE, PET and PEN would be particularly suitable for use in the making of a cover that is woven, braided, knitted or otherwise formed from fibres
Another embodiment of the distal portion of a clot receptor may comprise a combination of a self-expanding frame with a relatively non-porous membrane cover, and a plurality of flexible leaflets or vanes disposed around its outer circumference in a manner similar to that of a leaflet valve. In yet other embodiments the additional seal provided by these flexible leaflets is instead provided by an outer cuff, and this outer cuff may comprise a compressible material such as a foam or a hydrogel or a fibre bundle or a shaped polymer.
In yet another embodiment the expansion of the distal end of the clot receptor may be actuatable by the user, by retraction of a pull wire within the device shaft for example, or by inflation of a balloon cuff.
Some of the various embodiments of the distal end of the clot receptor are illustrated in
The intermediate catheter inner lumen may be as small as 0.75 mm or as large as 2.0 mm, but is preferably between 1.0 mm and 1.7 mm. The clot receptor distal end may be configured to expand to a diameter equal to or slightly larger than the target vessel in order to provide a seal, or to a diameter slightly smaller than the target vessel in cases where a low profile, deliverable device is a higher priority than a perfect seal. In one embodiment configured for use in middle cerebral arteries of the brain, the clot receptor distal end is configured to expand to a diameter of between 2 mm and 4 mm. In another embodiment such as might be used in the internal carotid artery, the clot receptor distal end is configured to expand to a diameter of between 4 mm and 7 mm.
Referring to
The aspiration catheter 101 is a rapid exchange (RX) catheter in which the exit port 105 defines a transfer port for aspiration and provides a deliverability advantage of minimal frictional engagement with the guide catheter 108 proximal of the exit port 105.
In some cases a microcatheter 109 may be provided through which a clot capture device 100 is delivered. Retracting the microcatheter 109 just proximal of the exit port 105 (rather than completely removing it) creates large aspiration advantage.
In one case the microcatheter 109 and the Rx aspiration catheter 101 are introduced together into the guide catheter 108.
The guide wire and microcatheter 109 are then advanced across the clot 110. The guidewire can be removed and a clot retrieval device such as a stent retriever device 100 is introduced.
Using the microcatheter 109 for support, the Rx aspiration catheter 101 can be forwarded to a position proximal to the clot 110 by pushing the proximal shaft 106 or handle into the guide catheter 108. The stentriever device 100 can be deployed by retracting the micro catheter 109.
The Rx aspiration catheter 101 can then be forwarded to contact the clot 110 or be positioned just proximal to or at the proximal face of the clot 110. The microcatheter 109 can then be retracted sufficiently to be proximal of the Rx port 105 of the Rx aspiration catheter 101. This facilitates an increased lumen for aspiration without the necessity of removing the microcatheter 109 fully from the intermediate/aspiration catheter.
Aspiration can be applied to the lumen of the guide catheter 108 with a manual syringe 111 or vacuum pump. This aspiration is directed to and effective at the distal tip 12 of the Rx aspiration catheter 101 due to the presence of the flow restrictor or seal 102 between the outer surface of the Rx aspiration catheter 101 and the inner guide catheter 108. This seals the lumen between the outside of the Rx aspiration catheter 101 and the inner lumen 103 of the guide catheter 108 and prevents backflow of blood into the tip of the guide catheter 108 which would reduce the effectiveness of the aspiration. The seal 102 may not need to stop flow in the lumen completely but needs to restrict flow sufficiently so as not to have a significant effect on aspiration performance. This seal 102 can be generated in a number of ways such as those described in
The Rx aspiration catheter 101 is constructed of a proximal handle (not shown) to facilitate grip and a proximal shaft 106 constructed from a wire or tube formed preferably from Nitinol, stainless steel, PEEK or some other similar material. An additional seal may be provided on a proximal haemostasis valve to assist in sealing against the proximal shaft 106. The material of the shaft 106 has high compressive and tensile strength and may have a low friction coating or jacket to minimise insertion and retraction forces. The low friction coating or jacket could be formed from PTFE, HDPE or a similar material.
The Rx exit port 105 on the aspiration catheter 101 can facilitate forwarding a microcatheter 109 through the port 105 and through the distal section 90 of the Rx catheter 101 prior to insertion into the guide catheter 108. The Rx exit port 105 may be formed in a funnel shape to make it easier to forward a microcatheter 109 into the port even in position in the guide catheter 108. The port 105 may be formed from a moulded component or from the tubing of the distal section 90 of the catheter 101.
The distal section of the Rx aspiration catheter 101 has good push and trackability characteristics to allow it to be forwarded to the target location. Therefore it may be constructed of one or more materials to give a reducing stiffness profile along the length. A braided wire or coil wire construction or combination of both may be used to improve compressive strength and track ability. Linear wire supports running parallel to the tube axis may also be used.
A top layer of low friction material may be applied to the distal section of the catheter 101 or alternatively a hydrophilic coating or silicon oil coating may be applied to the surface. The inner lining of the distal section of the catheter 101 consists of PTFE or similar low friction material to minimise insertion and retraction forces.
The seal 102 on the outer surface of the Rx aspiration catheter 101 distal section 90 prevents or significantly reduces blood flow travelling from the guide catheter distal tip 113 to the Rx port 105 of the Rx aspiration catheter 101 as shown in
In another embodiment of the device shown in
The seal 102 can be formed from an outer sleeve on the catheter which may be smooth or have a grooved or profiled surface 116 as shown in
In another embodiment illustrated in
In a further embodiment the seal 102 could be provided by a body 124 formed from a hydrophilic 124 or similar material which swells and increases in diameter when in contact with saline or blood. The seal 102 may also be formed by having a close tolerance clearance fit between the outer diameter of the distal end of the Rx aspiration catheter 101 and the inner diameter of the guide catheter 103. In another embodiment, the seal 102 is formed from a lip 118 or membrane 120 which restricts flow particularly in one direction as shown in
In another embodiment of the seal 102 shown in
The clot 110 and stentriever type device 100 can be fully or partially retrieved into the Rx aspiration catheter 101 as controlled by the physician and depending on the resistance felt by the user or clot obstruction of the lumen as indicated by an increase in vacuum/loss of suction. The expansile tip 112 of the Rx aspiration catheter 101 facilitates aspiration and retrieval of the clot 110 and stentriever device 100 by expanding under load to reduce the retraction force and lessen the risk of scraping clot off the surface of the stentriever device 100. The expansile tip 112 can also partially or fully occlude the vessel providing flow arrest improving aspiration effectiveness.
The expansile tip 112 can be formed in a number of ways and various embodiments are shown in
In one embodiment the expansile tip 112 can be formed from a co-extrusion of materials with different properties such as a soft expansile polymer 131 co-extruded with a higher modulus polymer 130 to provide longitudinal support. A fully expansile ring 132 could then be connected to this tip as shown in
The expansile tip may be pre shaped to form a flared profile (
The expansile tip 112 could also be profiled and contain one or more slot cuts 170 to facilitate expansion as shown in
In another embodiment of the Rx aspiration catheter tip 112 shown in
Referring to
In another embodiment of the catheter tip 112, shown in
Referring to
In another embodiment of the device shown in
The Rx aspiration catheter 101, microcatheter 109, stentriever device 100 and clot 110 can be retracted as a unit back to the tip of the guide catheter 113 and then fully into the guide catheter 108. The guide or access catheter 108 may also have an expansile tip 113 to facilitate retraction of the devices and clot, with a reduced force and lower risk of dislodging the clot from the devices. This expansile tip 113 on the guide catheter may be constructed in a similar manner to those shown in
The Rx aspiration catheter 101, microcatheter 109, stentriever device 100 and clot 110 can then be retrieved from the guide catheter 108 and removed fully from the patient.
Referring to
Use of a microcatheter with a removable hub that facilitates the use of an extension wire facilitates improved control on the microcatheter position as the intermediate catheter is introduced.
In
Referring to
Lumen A—a smaller diameter lumen can be used to retrieve the device into and cause the clot to shear off. The distal end of Lumen A could be flush with or recessed from the distal tip of Lumen B.
Lumen B—the larger lumen would have aspiration constantly applied to it, to aspirate the clot that is sheared off the device when it is retrieved into the smaller lumen (Lumen A).
The smaller lumen A may have an inner diameter to facilitate the introduction of a microcatheter through the lumen. The microcatheter can then be inserted through this lumen and across the clot as per standard procedure. The stentriever device can then be deployed across the clot. Retrieving the stentriever and clot into the catheter causes the clot to be sheared off the stentriever within the aspiration catheter. This configuration prevents the clot snagging on the struts of the stentriever device and blocking the aspiration lumen. The larger diameter lumen may have a diameter of about 0.058 inch and may have aspiration applied to it to aspirate the clot as the device is being retrieved into the smaller diameter lumen.
One clot receptor catheter tip according to the invention the clot receptor tip is expanded by means of a balloon, which may be attached to the shaft of a thrombectomy device, or to a microcatheter, or may be integral to the clot receptor catheter itself.
One embodiment of such a device is shown in these
The balloon expandable tip of the invention can be applied to any catheter—standard or rapid exchange, and can be used with or without a thrombectomy device to aid in the aspiration and/or retrieval of clot from blood vessels.
The actuatable flow restrictor or seal 504 comprises a framework 508, with a membrane covering 506. The framework 508 is at least partially collapsible by retraction of actuation member 512, which runs through proximal elongate shaft 501 and is connected at its proximal end to slider element 514, which is in turn slidably constrained within handle 513, and coupled to spring element 515. Proximal elongate shaft 501 may comprise a tube of stainless steel, Nitinol or other metallic or high modulus polymeric material, and may contain a liner in order to provide a low friction internal surface against which the actuation member 512 may slide. The shaft 501 may be tapered or may be slotted in order to provide a smooth transition in stiffness over its length. In the embodiment shown a portion of the shaft material has been removed from the distal portion 516 of shaft 501 in order to provide an exit port for actuation member 512 and to provide a connection member to the proximal end of tubular portion 502. This distal portion 516 may also be flattened, which may assist in creating a similar curvature to that of the tubular portion 502 so that the two portions can be smoothly joined together by welding, soldering, bonding or other appropriate method of fixation. The main body of the shaft may also have an oval or somewhat flattened profile, as this may be beneficial in allowing the user to seal a haemostasis valve around the shaft and a microcatheter when the two are side by side in the guide/sheath as shown previously in
The reinforcement member 507 may be formed from a metal (such as stainless steel or Nitinol or MP35N or other suitable alloy) or from a high modulus polymer material. In one embodiment (as shown) the reinforcent is formed from a tube from which sections 509 have been cut away to add lateral flexibility while maintaining column and hoop strength.
In the catheter illustrated in
In some scenarios, such as when retrieving a firm clot with a high fibrin content, it may not be possible to aspirate the clot fully into and through the RX clot removal catheter, and the clot may become lodged at the tip of the catheter. In such a case it may be necessary to remove the RX clot removal catheter with the clot through the guide catheter and out of the patient. It may be desirable to create reverse flow in the cerebral vasculature during this retrieval process in order to prevent the escape and distal migration of any fragments of the clot being retrieved. This can be done by disengaging the RX clot removal catheter seal so that the low pressure zone is redirected into the distal lumen of the guide catheter. Thus pressure gradient between the blood in the cerebral vasculature and the fluid within the guide catheter lumen causes a flow of the blood from the high pressure region to the low pressure region. The seal as shown can also serve to create a guiding feature to assist the advancement of another device into the tubular distal section of the clot removal catheter. This might be advantageous if for example the catheter was used as a primary clot debulking tool—so that it was advanced to a target clot and aspiration was applied to it through the guide catheter to remove the occlusive clot but was not successful in removing all of the clot. In this case a microcatheter (and guidewire if desired) could be advanced through the RX clot removal catheter and across the remaining clot so that a thrombectomy device could then be advanced through the microcatheter. The thrombectomy device and remaining clot could then be withdrawn into the RX clot removal catheter (under aspiration if desired) to complete the recanalisation of the patient's vessel.
The method of use of such a system could entail: Accessing the patient's vasculature using standard methods, advancing a guiding catheter or sheath 550 to a region proximal of the target occlusive clot 555, advancing the RX clot removal catheter 500 through the guide/sheath to a location proximal or adjacent to or within the target clot as shown in
This system enables a physician to use a standard guide or sheath to rapidly create an access path to the region of the target occlusion, and then use the Rx catheter 650 to quickly access and aspirate the target clot from the vessel. This system provides a major advantage in the speed and ease with which a physician will be able to access and retrieve the clot. The provision of the distal vessel seal 652 on the Rx catheter rather than on the guide or sheath means that this seal can be placed more distally in the vasculature, past the petris portion of the carotid vasculature when used in the ICA for example, which means less likelihood of vessel collapse when a suction force is applied, and less likelihood of vessel spasm.
In a preferred embodiment the flow restrictors/seals are actuatable and are formed from compliant balloons, which are inflated via a hollow shaft 657 by means of a syringe or inflator 653 applied to handle 654 of the Rx catheter 650. In other embodiments the proximal flow restrictor may be passive (i.e. it cannot be selectively activated or inactivated) as shown in several other designs in this disclosure. In yet other embodiments the distal seal may be actuated by means of an actuating member rather than an inflation lumen.
Most of the Rx (rapid exchange) catheters disclosed herein share some common features and geometry. Taking catheter 500 of
The optimal internal and external diameters of the Rx catheter depends very much on the site of the target clot and the size of the guide catheter or sheath through which the catheter is to be advanced. In the case of retrieval of occlusive clots from cerebral vessels the likely vessel diameters range from approximately 1.5 mm up to 6 mm, with 3 mm being a very typical diameter. Guide catheters/sheaths used in these scenarios have typically an internal diameter of between 0.060″ and 0.095″, so that a suitable system might consist of a guide catheter with an internal diameter of 0.078″ and an Rx clot retrieval catheter whose distal tubular section has an outside diameter of 0.070″ and an inside diameter of 0.062″. Such a system provides a very significant benefit in terms of flow resistance over an equivalently sized conventional combination of a guide and intermediate/aspiration (not rapid exchange) catheter. In particular the effective proximal lumen of the system of this invention is that of the guide catheter (0.078″), while the effective proximal lumen of the conventional system would be that of the intermediate/aspiration catheter (0.062″). This results in a significantly lower flow restriction in the Rx system of the invention, which means that for a given vacuum/suction force applied to the proximal end of the system, a much greater flow will be created through the system of this invention. While a conventional (not rapid exchange) intermediate/aspiration catheter may be stepped in diameter to maximise its proximal internal diameter, this proximal internal diameter must always be significantly smaller than the guide/sheath in which it is positioned. This is not the case in the system of this invention.
Yet another embodiment of this invention is shown in
Therefore when actuated by pulling as shown in
Similarly when the control member is pushed forward it can cause or allow the catheter tip to expand forming a funnel shape as shown in
In use the control member may be pulled back during insertion of the catheter to improve accessibility. It can then be forwarded to increase the diameter of the tip and aspirate the occlusion.
If the occlusion or blood clot can only be partially aspirated, then the tip diameter can be reduced again by pulling the control member, causing the clot to be trapped as shown in
The flaps 703 of the catheter tip are not rigidly connected to the integrated control member 701 but form a loop which can slide over the control member. The control member distal end 706 may also be fixed to the inner surface of the catheter.
Referring to
One embodiment of the method of use of such a system could consist of the following steps: Accessing an arterial blood vessel of a patient using conventional means such as an introducer and guide catheter 808 and/or sheath, advancing Rx aspiration catheter 801 through a first branch of RHV 813 attached to proximal end of guide catheter 808, advancing a microcatheter 809 through a second branch of RHV 813 and through the aspiration catheter 801 and guide catheter 808 up to and across a target occlusive clot 810 with or without the aid of a guidewire, removing the guidewire (if used) and advancing a mechanical thrombectomy device 800 such as a stent-retriever through the microcatheter 809 to the target clot 810, retracting the microcatheter 809 at least a few cm to deploy a mechanical thrombectomy device 800 within the clot 810, advancing the aspiration catheter 801 up to a position just proximal of the clot 810 (or within the clot, or considerably proximal of the clot if vessel disease or tortuosity makes access difficult), optionally creating flow arrest by inflating the balloon of the guide catheter 808 (if used, or by other means), aspirating through the aspiration catheter 801 using a syringe 811 or pump connected to the guide catheter 808 while withdrawing the mechanical thrombectomy device 800 towards and into the distal mouth 812 of the aspiration catheter 801, withdrawing the clot 810, mechanical thrombectomy device 800 and microcatheter 809 through the aspiration catheter 801 and guide catheter 808 and out of the patient while continuing to aspirate.
A possible variant of the final step of the above method could involve removing the aspiration catheter along with the clot 810, mechanical thrombectomy device 800 and microcatheter 809. This variant is useful if a large and/or firm clot is encountered which the physician cannot (or does not wish to) fully withdraw into the mouth of the aspiration catheter. In such a situation the RHV 813 must be removed once the exit port 805 of the aspiration catheter 801 reaches the RHV 813.
Another method of use of such an Rx aspiration catheter system is to retrieve clot using aspiration without the use of a thrombectomy device. The rapid exchange shaft of this invention provides great advantages in terms of speed, deliverability, ease of use and aspiration lumen. A microcatheter or other similar catheter and guidewire nay be used to provide support to assist in tracking the aspiration catheter to the target site in a similar manner to that illustrated in either
It will be apparent from the foregoing description that while particular embodiments of the present invention have been illustrated and described, various modifications can be made without departing from the spirit and scope of the invention. For example, while the embodiments described herein refer to particular features, the invention includes embodiments having different combinations of features. The invention also includes embodiments that do not include all of the specific features described.
The invention is not limited to the embodiments hereinbefore described which may be varied in construction and detail.
This application is a continuation of U.S. application Ser. No. 14/737,249, filed Jun. 11, 2015, currently pending, which claims the benefit of U.S. Provisional Application No. 62/011,934, filed Jun. 13, 2014, and U.S. Provisional No. 62/080,724, filed Nov. 17, 2014, all of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4243040 | Beecher | Jan 1981 | A |
4738666 | Fuqua | Apr 1988 | A |
4767404 | Renton | Aug 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4873978 | Ginsburg | Oct 1989 | A |
5011488 | Ginsburg | Apr 1991 | A |
5092839 | Kipperman | Mar 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5123840 | Nates | Jun 1992 | A |
5171233 | Amplatz | Dec 1992 | A |
5234437 | Sepetka | Aug 1993 | A |
5385562 | Adams et al. | Jan 1995 | A |
5387219 | Rappe | Feb 1995 | A |
5387226 | Miraki | Feb 1995 | A |
5449372 | Schmaltz | Sep 1995 | A |
5520651 | Sutcu | May 1996 | A |
5538512 | Zenzon et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5558652 | Henke | Sep 1996 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5639277 | Mariant | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5658296 | Bates | Aug 1997 | A |
5662671 | Barbut | Sep 1997 | A |
5695519 | Summer et al. | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713853 | Clark | Feb 1998 | A |
5728078 | Powers, Jr. | Mar 1998 | A |
5769871 | Mers Kelly | Jun 1998 | A |
5779716 | Cano | Jul 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Daniel et al. | Sep 1998 | A |
5827304 | Hart | Oct 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5893869 | Barnhart et al. | Apr 1999 | A |
5895398 | Wensel | Apr 1999 | A |
5897567 | Ressemann | Apr 1999 | A |
5904698 | Thomas et al. | May 1999 | A |
5911725 | Boury | Jun 1999 | A |
5935139 | Bates | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5968057 | Taheri | Oct 1999 | A |
6063113 | Kavteladze | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson | May 2000 | A |
6093196 | Okada | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates | Aug 2000 | A |
6102932 | Kurz | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6146404 | Kim | Nov 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6168604 | Cano | Jan 2001 | B1 |
6179861 | Khosravi | Jan 2001 | B1 |
6203561 | Ramee | Mar 2001 | B1 |
6214026 | Lepak | Apr 2001 | B1 |
6221006 | Dubrul | Apr 2001 | B1 |
6238412 | Dubrul | May 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6254571 | Hart | Jul 2001 | B1 |
6264663 | Cano | Jul 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6309379 | Willard et al. | Oct 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6348056 | Bates | Feb 2002 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6361545 | Macoviak | Mar 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6383206 | Gillick | May 2002 | B1 |
6402771 | Palmer | Jun 2002 | B1 |
6416541 | Denardo | Jul 2002 | B2 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6432122 | Gilson et al. | Aug 2002 | B1 |
6436112 | Wensel | Aug 2002 | B2 |
6458139 | Palmer | Oct 2002 | B1 |
6485497 | Wensel | Nov 2002 | B2 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Don Michael | Nov 2002 | B2 |
6511492 | Rosenbluth | Jan 2003 | B1 |
6520951 | Carrillo, Jr. et al. | Feb 2003 | B1 |
6530935 | Wensel | Mar 2003 | B2 |
6530939 | Hopkins | Mar 2003 | B1 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6544279 | Hopkins | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6582448 | Boyle | Jun 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6592616 | Stack | Jul 2003 | B1 |
6602271 | Adams | Aug 2003 | B2 |
6602272 | Boylan et al. | Aug 2003 | B2 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6638245 | Miller | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6685722 | Rosenbluth | Feb 2004 | B1 |
6692504 | Kurz et al. | Feb 2004 | B2 |
6692508 | Wensel | Feb 2004 | B2 |
6692509 | Wensel | Feb 2004 | B2 |
6702782 | Miller | Mar 2004 | B2 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6730104 | Sepetka | May 2004 | B1 |
6824545 | Sepetka | Nov 2004 | B2 |
6855155 | Denardo et al. | Feb 2005 | B2 |
6878163 | Denardo et al. | Apr 2005 | B2 |
6890340 | Duane | May 2005 | B2 |
6913612 | Palmer | Jul 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6989019 | Mazzocchi | Jan 2006 | B2 |
6994718 | Groothuis et al. | Feb 2006 | B2 |
6997939 | Linder et al. | Feb 2006 | B2 |
7004954 | Voss et al. | Feb 2006 | B1 |
7004955 | Shen | Feb 2006 | B2 |
7004956 | Palmer | Feb 2006 | B2 |
7008434 | Kurz et al. | Mar 2006 | B2 |
7033376 | Tsukernik | Apr 2006 | B2 |
7041116 | Goto | May 2006 | B2 |
7048758 | Boyle | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7063707 | Bose | Jun 2006 | B2 |
7153320 | Euteneuer | Dec 2006 | B2 |
7175655 | Malaei | Feb 2007 | B1 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7220269 | Ansel | May 2007 | B1 |
7220271 | Clubb | May 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7232462 | Schaeffer | Jun 2007 | B2 |
7288112 | Denardo et al. | Oct 2007 | B2 |
7306618 | Demond | Dec 2007 | B2 |
7316692 | Huffmaster | Jan 2008 | B2 |
7323001 | Clubb | Jan 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7344550 | Carrison et al. | Mar 2008 | B2 |
7399308 | Borillo et al. | Jul 2008 | B2 |
7410491 | Hopkins | Aug 2008 | B2 |
7452496 | Brady et al. | Nov 2008 | B2 |
7491215 | Vale et al. | Feb 2009 | B2 |
7491216 | Brady | Feb 2009 | B2 |
7510565 | Gilson et al. | Mar 2009 | B2 |
7534252 | Sepetka | May 2009 | B2 |
7556636 | Mazzocchi | Jul 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7594926 | Linder | Sep 2009 | B2 |
7604649 | McGuckin et al. | Oct 2009 | B2 |
7618434 | Santra | Nov 2009 | B2 |
7662165 | Gilson et al. | Feb 2010 | B2 |
7670356 | Mazzocchi | Mar 2010 | B2 |
7691121 | Rosenbluth | Apr 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7708770 | Linder | May 2010 | B2 |
7736385 | Agnew | Jun 2010 | B2 |
7766934 | Pal | Aug 2010 | B2 |
7771452 | Pal | Aug 2010 | B2 |
7780694 | Palmer | Aug 2010 | B2 |
7828815 | Mazzocchi | Nov 2010 | B2 |
7846176 | Mazzocchi | Nov 2010 | B2 |
7846175 | Bonnette et al. | Dec 2010 | B2 |
7850708 | Pal | Dec 2010 | B2 |
7887560 | Kusleika | Feb 2011 | B2 |
7901426 | Gilson et al. | Mar 2011 | B2 |
7914549 | Morsi | Mar 2011 | B2 |
7922732 | Mazzocchi | Apr 2011 | B2 |
7927784 | Simpson | Apr 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7998165 | Huffmaster | Aug 2011 | B2 |
8002822 | Glocker et al. | Aug 2011 | B2 |
8021379 | Thompson et al. | Sep 2011 | B2 |
8021380 | Thompson et al. | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8057497 | Raju et al. | Nov 2011 | B1 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8100935 | Rosenbluth et al. | Jan 2012 | B2 |
8109941 | Richardson | Feb 2012 | B2 |
8118829 | Carrison et al. | Feb 2012 | B2 |
8123769 | Osborne | Feb 2012 | B2 |
8137377 | Palmer et al. | Mar 2012 | B2 |
8142422 | Makower et al. | Mar 2012 | B2 |
8142442 | Palmer et al. | Mar 2012 | B2 |
8182508 | Magnuson et al. | May 2012 | B2 |
8187298 | Pal | May 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8246672 | Osborne | Aug 2012 | B2 |
8252017 | Paul, Jr. et al. | Aug 2012 | B2 |
8252018 | Valaie | Aug 2012 | B2 |
8357178 | Grandfield et al. | Jan 2013 | B2 |
8357179 | Grandfield et al. | Jan 2013 | B2 |
8361095 | Osborne | Jan 2013 | B2 |
8366663 | Fiorella et al. | Feb 2013 | B2 |
8372133 | Douk | Feb 2013 | B2 |
8409215 | Sepetka et al. | Apr 2013 | B2 |
8419748 | Valaie | Apr 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8460313 | Huffmaster | Jun 2013 | B2 |
8486104 | Samson et al. | Jul 2013 | B2 |
8529596 | Grandfield et al. | Sep 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8579915 | French et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8608761 | Osborne et al. | Dec 2013 | B2 |
8679142 | Slee et al. | Mar 2014 | B2 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8702652 | Fiorella et al. | Apr 2014 | B2 |
8702724 | Olsen et al. | Apr 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784441 | Rosenbluth et al. | Jul 2014 | B2 |
8795305 | Grandfield et al. | Aug 2014 | B2 |
8795317 | Grandfield et al. | Aug 2014 | B2 |
8814925 | Hilaire et al. | Aug 2014 | B2 |
8900265 | Ulm, III | Dec 2014 | B1 |
8939991 | Krolick et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8968330 | Rosenbluth et al. | Mar 2015 | B2 |
9039749 | Shrivastava et al. | May 2015 | B2 |
9072537 | Grandfield et al. | Jul 2015 | B2 |
9113936 | Palmer et al. | Aug 2015 | B2 |
9119656 | Bose et al. | Sep 2015 | B2 |
9138307 | Valaie | Sep 2015 | B2 |
9155552 | Ulm, III | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9173668 | Ulm, III | Nov 2015 | B2 |
9186487 | Dubrul et al. | Nov 2015 | B2 |
9198687 | Fulkerson et al. | Dec 2015 | B2 |
9204887 | Cully et al. | Dec 2015 | B2 |
9221132 | Bowman | Dec 2015 | B2 |
20010001315 | Bates | May 2001 | A1 |
20010016755 | Addis | Aug 2001 | A1 |
20010041899 | Foster | Nov 2001 | A1 |
20010044598 | Parodi | Nov 2001 | A1 |
20010051810 | Dubrul | Dec 2001 | A1 |
20020002383 | Sepetka | Jan 2002 | A1 |
20020016609 | Wensel | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026211 | Khosravi | Feb 2002 | A1 |
20020049468 | Streeter | Apr 2002 | A1 |
20020052620 | Barbut | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020072764 | Sepetka | Jun 2002 | A1 |
20020082558 | Samson | Jun 2002 | A1 |
20020091407 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020095171 | Belef | Jul 2002 | A1 |
20020123765 | Sepetka | Sep 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20020161393 | Demond | Oct 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020173819 | Leeflang et al. | Nov 2002 | A1 |
20020188276 | Evans | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030004538 | Secrest | Jan 2003 | A1 |
20030004542 | Wensel | Jan 2003 | A1 |
20030009146 | Muni | Jan 2003 | A1 |
20030009191 | Wensel | Jan 2003 | A1 |
20030040769 | Kelley et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin | Mar 2003 | A1 |
20030125798 | Martin | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030153943 | Michael et al. | Aug 2003 | A1 |
20030153944 | Phung | Aug 2003 | A1 |
20030163064 | Vrba | Aug 2003 | A1 |
20030163158 | White | Aug 2003 | A1 |
20030171769 | Barbut | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030195537 | Dubrul | Oct 2003 | A1 |
20030195554 | Shen | Oct 2003 | A1 |
20030199917 | Knudson | Oct 2003 | A1 |
20030204202 | Palmer | Oct 2003 | A1 |
20030212430 | Bose | Nov 2003 | A1 |
20030236533 | Wilson | Dec 2003 | A1 |
20040010280 | Adams | Jan 2004 | A1 |
20040014002 | Lundgren | Jan 2004 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka | Apr 2004 | A1 |
20040079429 | Miller | Apr 2004 | A1 |
20040082962 | Demarais et al. | Apr 2004 | A1 |
20040093065 | Yachia et al. | May 2004 | A1 |
20040133231 | Maitland | Jul 2004 | A1 |
20040138692 | Phung | Jul 2004 | A1 |
20040153118 | Clubb | Aug 2004 | A1 |
20040193107 | Pierpont et al. | Sep 2004 | A1 |
20040260333 | Dubrul et al. | Dec 2004 | A1 |
20050020974 | Noriega | Jan 2005 | A1 |
20050033348 | Sepetka | Feb 2005 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050049619 | Sepetka | Mar 2005 | A1 |
20050049669 | Jones | Mar 2005 | A1 |
20050049670 | Jones et al. | Mar 2005 | A1 |
20050055033 | Leslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059995 | Sepetka | Mar 2005 | A1 |
20050085849 | Sepetka | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050125024 | Sepetka | Jun 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050216030 | Sepetka | Sep 2005 | A1 |
20050216050 | Sepetka | Sep 2005 | A1 |
20050228417 | Teitelbaum et al. | Oct 2005 | A1 |
20050267491 | Kellett et al. | Dec 2005 | A1 |
20050288686 | Sepetka | Dec 2005 | A1 |
20060009799 | Kleshinski et al. | Jan 2006 | A1 |
20060058836 | Bose | Mar 2006 | A1 |
20060058837 | Bose | Mar 2006 | A1 |
20060058838 | Bose | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060106361 | Muni | May 2006 | A1 |
20060155305 | Freudenthal | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060195137 | Sepetka | Aug 2006 | A1 |
20060224177 | Finitsis | Oct 2006 | A1 |
20060224179 | Kucharczyk | Oct 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20060287701 | Pal | Dec 2006 | A1 |
20070088383 | Pal et al. | Apr 2007 | A1 |
20070156170 | Hancock | Jul 2007 | A1 |
20070165170 | Fukuda | Jul 2007 | A1 |
20070191866 | Palmer et al. | Aug 2007 | A1 |
20070198028 | Miloslavski | Aug 2007 | A1 |
20070198051 | Clubb et al. | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070208367 | Fiorella | Sep 2007 | A1 |
20070208371 | French | Sep 2007 | A1 |
20070225749 | Martin | Sep 2007 | A1 |
20070239254 | Chia et al. | Oct 2007 | A1 |
20070244505 | Gilson et al. | Oct 2007 | A1 |
20070288038 | Bimbo | Dec 2007 | A1 |
20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
20080082107 | Miller et al. | Apr 2008 | A1 |
20080086190 | Ta | Apr 2008 | A1 |
20080091223 | Pokorney | Apr 2008 | A1 |
20080097398 | Mitelberg | Apr 2008 | A1 |
20080109031 | Sepetka | May 2008 | A1 |
20080109032 | Sepetka | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080177296 | Sepetka | Jul 2008 | A1 |
20080183197 | Sepetka | Jul 2008 | A1 |
20080183198 | Sepetka | Jul 2008 | A1 |
20080183205 | Sepetka | Jul 2008 | A1 |
20080188876 | Sepetka | Aug 2008 | A1 |
20080188885 | Sepetka | Aug 2008 | A1 |
20080188928 | Salahieh | Aug 2008 | A1 |
20080200946 | Braun | Aug 2008 | A1 |
20080215077 | Sepetka | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080228209 | DeMello et al. | Sep 2008 | A1 |
20080234706 | Sepetka | Sep 2008 | A1 |
20080243170 | Jenson | Oct 2008 | A1 |
20080255596 | Jenson | Oct 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20080275488 | Fleming | Nov 2008 | A1 |
20080275493 | Farmiga | Nov 2008 | A1 |
20080312681 | Ansel | Dec 2008 | A1 |
20090024157 | Anukhin | Jan 2009 | A1 |
20090069828 | Martin | Mar 2009 | A1 |
20090076539 | Valaie | Mar 2009 | A1 |
20090105722 | Fulkerson | Apr 2009 | A1 |
20090105737 | Fulkerson | Apr 2009 | A1 |
20090270815 | Stamp et al. | Oct 2009 | A1 |
20090292297 | Ferrere | Nov 2009 | A1 |
20090292307 | Razack | Nov 2009 | A1 |
20090299393 | Martin | Dec 2009 | A1 |
20090306702 | Miloslavski | Dec 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100030186 | Stivland | Feb 2010 | A1 |
20100087908 | Hilaire | Apr 2010 | A1 |
20100114017 | Lenker | May 2010 | A1 |
20100125326 | Kalstad | May 2010 | A1 |
20100125327 | Agnew | May 2010 | A1 |
20100191272 | Keating | Jul 2010 | A1 |
20100211094 | Sargent, Jr. | Aug 2010 | A1 |
20100249815 | Jantzen | Sep 2010 | A1 |
20100268264 | Bonnett et al. | Oct 2010 | A1 |
20100268265 | Krolik et al. | Oct 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20100331949 | Habib | Dec 2010 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110009940 | Grandfield et al. | Jan 2011 | A1 |
20110009942 | Gregorich | Jan 2011 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110054514 | Arcand | Mar 2011 | A1 |
20110054516 | Keegan | Mar 2011 | A1 |
20110060359 | Hannes | Mar 2011 | A1 |
20110077620 | deBeer | Mar 2011 | A1 |
20110054504 | Wolf et al. | May 2011 | A1 |
20110125181 | Brady et al. | May 2011 | A1 |
20110152920 | Eckhouse et al. | Jun 2011 | A1 |
20110160763 | Ferrera et al. | Jun 2011 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110196414 | Porter et al. | Aug 2011 | A1 |
20110202088 | Eckhouse et al. | Aug 2011 | A1 |
20110213290 | Chin | Sep 2011 | A1 |
20110213297 | Aklog et al. | Sep 2011 | A1 |
20110213403 | Aboytes | Sep 2011 | A1 |
20110224707 | Miloslavaski et al. | Sep 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110319917 | Ferrera et al. | Dec 2011 | A1 |
20120041449 | Eckhouse et al. | Feb 2012 | A1 |
20120041474 | Eckhouse et al. | Feb 2012 | A1 |
20120059356 | diPalma et al. | Mar 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120116351 | Chomas | May 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120150147 | Leynov et al. | Jun 2012 | A1 |
20120165858 | Eckhouse et al. | Jun 2012 | A1 |
20120165859 | Eckhouse et al. | Jun 2012 | A1 |
20120277788 | Cattaneo | Nov 2012 | A1 |
20120296362 | Cam et al. | Nov 2012 | A1 |
20130030461 | Marks et al. | Jan 2013 | A1 |
20130046330 | McIntosh et al. | Feb 2013 | A1 |
20130046333 | Jones et al. | Feb 2013 | A1 |
20130046334 | Jones et al. | Feb 2013 | A1 |
20130116774 | Strauss et al. | May 2013 | A1 |
20130144326 | Brady et al. | Jun 2013 | A1 |
20130158592 | Porter | Jun 2013 | A1 |
20130184739 | Brady et al. | Jul 2013 | A1 |
20130197567 | Brady et al. | Aug 2013 | A1 |
20130226146 | Tekulve | Aug 2013 | A1 |
20130268050 | Wilson et al. | Oct 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20130325055 | Eckhouse et al. | Dec 2013 | A1 |
20130325056 | Eckhouse et al. | Dec 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140046359 | Bowman et al. | Feb 2014 | A1 |
20140121672 | Folk | May 2014 | A1 |
20140128905 | Molaei | May 2014 | A1 |
20140180377 | Bose et al. | Jun 2014 | A1 |
20140194919 | Losordo et al. | Jul 2014 | A1 |
20140200608 | Brady et al. | Jul 2014 | A1 |
20140236220 | Inoue | Aug 2014 | A1 |
20140257362 | Eidenschink | Sep 2014 | A1 |
20140276922 | McLain et al. | Sep 2014 | A1 |
20140277079 | Vale et al. | Sep 2014 | A1 |
20140309657 | Ben-Ami | Oct 2014 | A1 |
20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
20140330302 | Tekulve et al. | Nov 2014 | A1 |
20140343585 | Ferrera et al. | Nov 2014 | A1 |
20140371769 | Vale et al. | Dec 2014 | A1 |
20140371779 | Vale et al. | Dec 2014 | A1 |
20140371780 | Vale et al. | Dec 2014 | A1 |
20140379023 | Brady et al. | Dec 2014 | A1 |
20150018859 | Quick et al. | Jan 2015 | A1 |
20150018860 | Quick et al. | Jan 2015 | A1 |
20150080937 | Davidson | Mar 2015 | A1 |
20150112376 | Molaei et al. | Apr 2015 | A1 |
20150133990 | Davidson | May 2015 | A1 |
20150164523 | Brady et al. | Jun 2015 | A1 |
20150250497 | Marks et al. | Sep 2015 | A1 |
20150257775 | Gilvarry et al. | Sep 2015 | A1 |
20150297252 | Miloslavski et al. | Oct 2015 | A1 |
20150313617 | Grandfield et al. | Nov 2015 | A1 |
20150320431 | Ulm, III | Nov 2015 | A1 |
20150352325 | Quick | Dec 2015 | A1 |
20150359547 | Vale et al. | Dec 2015 | A1 |
20150374391 | Quick et al. | Dec 2015 | A1 |
20150374393 | Brady et al. | Dec 2015 | A1 |
20150374479 | Vale | Dec 2015 | A1 |
20160015402 | Brady et al. | Jan 2016 | A1 |
20160022296 | Brady et al. | Jan 2016 | A1 |
20160066921 | Seifert et al. | Mar 2016 | A1 |
20160106448 | Brady et al. | Apr 2016 | A1 |
20160106449 | Brady et al. | Apr 2016 | A1 |
20160113663 | Brady et al. | Apr 2016 | A1 |
20160113664 | Brady et al. | Apr 2016 | A1 |
20160113665 | Brady et al. | Apr 2016 | A1 |
20160120558 | Brady et al. | May 2016 | A1 |
20160121080 | Cottone | May 2016 | A1 |
20160143653 | Vale et al. | May 2016 | A1 |
20160192953 | Brady et al. | Jul 2016 | A1 |
20160192954 | Brady et al. | Jul 2016 | A1 |
20160192955 | Brady et al. | Jul 2016 | A1 |
20160192956 | Brady et al. | Jul 2016 | A1 |
Number | Date | Country |
---|---|---|
202009001951 | Apr 2010 | DE |
102009056450 | Jun 2011 | DE |
102010010849 | Sep 2011 | DE |
10 2010 014778 | Oct 2011 | DE |
102010024085 | Dec 2011 | DE |
102011014586 | Sep 2012 | DE |
2301450 | Nov 2011 | EP |
2628455 | Aug 2013 | EP |
0919438 | Jan 1997 | JP |
WO 9424926 | Nov 1994 | WO |
WO 9727808 | Aug 1997 | WO |
WO 9738631 | Oct 1997 | WO |
WO 9920335 | Apr 1999 | WO |
WO 9960933 | Dec 1999 | WO |
WO 9956801 | Apr 2000 | WO |
WO 0121077 | Mar 2001 | WO |
WO 2004056275 | Jul 2001 | WO |
WO 0202162 | Jan 2002 | WO |
WO 0211627 | Feb 2002 | WO |
WO 0243616 | Jun 2002 | WO |
WO 02070061 | Sep 2002 | WO |
WO 02094111 | Nov 2002 | WO |
WO 03002006 | Jan 2003 | WO |
WO 03030751 | Apr 2003 | WO |
WO 03051448 | Jun 2003 | WO |
WO 2004028571 | Apr 2004 | WO |
WO 2005000130 | Jan 2005 | WO |
WO 2005027779 | Mar 2005 | WO |
WO 2006021407 | Mar 2006 | WO |
WO 2006031410 | Mar 2006 | WO |
WO 2006107641 | Oct 2006 | WO |
WO 2006135823 | Dec 2006 | WO |
WO 2007054307 | May 2007 | WO |
WO 2007068424 | Jun 2007 | WO |
WO 2008034615 | Mar 2008 | WO |
WO 2008051431 | May 2008 | WO |
WO 2008131116 | Oct 2008 | WO |
WO 2009031338 | Mar 2009 | WO |
WO 2009076482 | Jun 2009 | WO |
WO 2009086482 | Jul 2009 | WO |
WO 2009105710 | Aug 2009 | WO |
WO 2010010545 | Jan 2010 | WO |
WO 2010046897 | Apr 2010 | WO |
WO 2010075565 | Jul 2010 | WO |
WO 2010102307 | Sep 2010 | WO |
WO 2010146581 | Dec 2010 | WO |
WO 2011013556 | Feb 2011 | WO |
WO 2011066961 | Jun 2011 | WO |
WO 2011082319 | Jul 2011 | WO |
WO 2011095352 | Aug 2011 | WO |
WO 2011110316 | Sep 2011 | WO |
WO 2012052982 | Apr 2012 | WO |
WO 2012064726 | May 2012 | WO |
WO 2012081020 | Jun 2012 | WO |
WO 2012120490 | Sep 2012 | WO |
WO 2012110619 | Oct 2012 | WO |
2012156924 | Nov 2012 | WO |
WO 2013016435 | Jan 2013 | WO |
WO 2013072777 | May 2013 | WO |
WO 2013105099 | Jul 2013 | WO |
WO 2013109756 | Jul 2013 | WO |
WO 2014081892 | May 2014 | WO |
WO 2014139845 | Sep 2014 | WO |
WO 2014169266 | Oct 2014 | WO |
WO 2014178198 | Nov 2014 | WO |
WO 2015061365 | Apr 2015 | WO |
WO 2015134625 | Sep 2015 | WO |
WO 2015179324 | Nov 2015 | WO |
2015189354 | Dec 2015 | WO |
WO 2016010995 | Jan 2016 | WO |
Entry |
---|
US 6,348,062 B1, 02/2002, Hopkins (withdrawn) |
Office Action issued in U.S. Appl. No. 14/737,249 dated Apr. 10, 2018. |
Partial European Search Report issued in Application 17204015.6 dated May 17, 2018. |
Number | Date | Country | |
---|---|---|---|
20160256180 A1 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
62080724 | Nov 2014 | US | |
62011934 | Jun 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14737249 | Jun 2015 | US |
Child | 15158384 | US |